Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inlexisertib in Advanced Solid Tumors With RAS/MAPK Pathway Mutations
NCT04892017Phase 1Terminated
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inlexisertib in non-small cell lung cancer (NSCLC) and solid tumor (6 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Incidence of Adverse Events at 24 months, Maximum tolerated dose at 18 months and 1 more. Started Jun 2021; status: terminated.
02
Drugs
inlexisertib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04892017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892017.